Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $2.1 million.

  • Vistagen Therapeutics' Cash from Financing Activities rose 8035.87% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $33.2 million, marking a year-over-year increase of 367758.82%. This contributed to the annual value of $3.2 million for FY2025, which is 9750.0% down from last year.
  • As of Q4 2025, Vistagen Therapeutics' Cash from Financing Activities stood at $2.1 million, which was up 8035.87% from $27.7 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Cash from Financing Activities registered a high of $93.7 million during Q4 2023, and its lowest value of -$397400.0 during Q1 2023.
  • Its 5-year average for Cash from Financing Activities is $9.3 million, with a median of $1.2 million in 2024.
  • Data for Vistagen Therapeutics' Cash from Financing Activities shows a peak YoY increase of 3092242.68% (in 2023) and a maximum YoY decrease of 177679.32% (in 2023) over the last 5 years.
  • Vistagen Therapeutics' Cash from Financing Activities (Quarter) stood at $2.1 million in 2021, then plummeted by 114.35% to -$304100.0 in 2022, then soared by 30922.43% to $93.7 million in 2023, then crashed by 98.75% to $1.2 million in 2024, then skyrocketed by 80.36% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q4 2025, $27.7 million for Q3 2025, and $1.5 million during Q2 2025.